Clinical Trial Update: Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a combination of immunotherapy, hormone therapy, and an AKT inhibitor for premenopausal, ER-positive metastatic breast cancer;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• AKT inhibitor (unspecified)
• Hormone therapy (unspecified)
• Immunotherapy (unspecified)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Premenopausal Breast Cancer, Metastatic Breast Cancer | Phase 2 | Status: RECRUITING